If I might continue, Madam Chair, I should be clear here about the role. Health Canada is very concerned about the strict screening and the safety, because we are the regulator. We are very concerned about the safety of these products. That is our role, to make sure nothing in any process or any part of the process will affect the safety of the products.
Provincial and territorial governments have the authority to deal with the question of compensation, whether it is for blood, cells, tissues, or organs. We know that some jurisdictions, notably Quebec, have made a provision that they are not compensating for any of these. Other provinces—and I mentioned that this is a long-standing practice in at least one jurisdiction in Canada. This is, therefore, something we are in dialogue, again, with our provincial and territorial colleagues about, as the payment question is one in their jurisdiction.
The Canadian Blood Services and Héma-Québec are also involved. Obviously, patients who rely on these products.... We held an initial consultation with groups that are very reliant on some of these specialist products. But as I say, currently 70% of them are sourced from plasma from paid donors, so this group of people also has a voice and an interest in this topic.
We are working with our provincial and territorial colleagues. We have the safety mandate; they have the payment question.